Story

Genmab Stock Surges on Q2 Earnings Beat and Upgraded Outlook

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Genmab Stock Surges on Q2 Earnings Beat and Upgraded Outlook
Text size
Background

Shares of Genmab (GMAB) surged 9.2% to DKK 2,050 in trading after the Danish biotechnology company reported a strong second-quarter earnings beat, raised its full-year financial guidance, and announced positive clinical and regulatory updates.

Stronger-Than-Expected Financials

Genmab posted second-quarter earnings per share of $0.49, significantly exceeding the consensus analyst estimate of $0.37. Quarterly revenue also came in ahead of expectations at $1.16 billion, compared to the $1.11 billion anticipated by analysts.

Following the strong performance, the company lifted its full-year revenue guidance to a new range of $4.325 billion to $4.525 billion. According to the company, the improved outlook is driven by expectations for higher royalty revenues from its cancer drug DARZALEX and stronger net sales of EPKINLY.

Clinical and Commercial Momentum

The company's growth was underpinned by robust product performance and key pipeline developments. Genmab highlighted several positive updates:

Sample IUX Markets – In-articleAd
  • Royalty revenue reached $1.708 billion, a year-over-year increase of 24%.
  • Global net sales for EPKINLY/TEPKINLY surged 48% to $312 million.
  • The Phase III EPCORE DLBCL-2 study delivered statistically significant and clinically meaningful results for progression-free survival.
  • EPKINLY received European approval for use in combination with other therapies for second-line follicular lymphoma.

In a statement, CEO Jan van de Winkel noted that its drug epcoritamab "continued to demonstrate its potential as a core therapy across the spectrum of B-cell malignancies."

Market Context

The sharp upward move in Genmab's stock was amplified by a positive backdrop for the broader European healthcare sector, which rose 1.3% during the session. The combination of a substantial earnings beat, an increased forecast, and favorable drug development news provided investors with multiple catalysts to drive the stock higher, pushing it toward the upper end of its 52-week trading range of DKK 1,337 to DKK 2,257.

Read next

More on Stocks
Back to latest news

LATEST